CA
NZ
UK
AU
IND
US
…
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -282.60M | -158.13M | -520.12M | -445.72M | -386.21M |
| Net income | -296.80M | -177.03M | -518.25M | -446.35M | -386.21M |
| Selling general administrative | 135.80M | 136.78M | 106.77M | 80.63M | 46.94M |
| Selling and marketing expenses | 205.80M | 147.48M | 94.16M | 93.42M | 102.54M |
| Gross profit | 620.80M | 392.66M | 140.93M | 51.64M | 89.79M |
| Reconciled depreciation | 28.90M | 23.36M | 20.35M | 18.39M | 13.92M |
| Ebit | -261.20M | -136.52M | -498.32M | -455.83M | -393.02M |
| Ebitda | -232.30M | -113.16M | -477.87M | -437.44M | -379.11M |
| Depreciation and amortization | 28.90M | 23.36M | 20.45M | 18.39M | 13.92M |
| Operating income | -136.50M | -303.24M | -439.49M | -455.83M | -393.02M |
| Other operating expenses | 1165.40M | 930.48M | 724.63M | 575.06M | 462.83M |
| Interest expense | 21.40M | 21.61M | 21.79M | 10.80M | 0.90M |
| Tax provision | 14.20M | 18.89M | 0.28M | 0.62M | 0.00M |
| Interest income | 40.10M | 61.20M | 42.07M | 8.18M | 0.97M |
| Net interest income | 18.70M | 39.59M | 21.24M | -10.80M | -0.90M |
| Income tax expense | 14.20M | 18.89M | -1.86M | 0.62M | 0.00M |
| Total revenue | 1028.90M | 627.24M | 285.14M | 117.00M | 89.79M |
| Total operating expenses | 757.30M | 695.90M | 580.41M | 509.70M | 462.83M |
| Cost of revenue | 408.10M | 234.58M | 144.21M | 65.36M | - |
| Total other income expense net | -146.10M | 145.11M | -80.63M | 10.10M | 6.82M |
| Net income from continuing ops | -296.80M | -177.03M | -509.31M | -446.35M | -386.21M |
| Net income applicable to common shares | - | - | - | -446.35M | -386.21M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 1733.70M | 1670.15M | 1848.61M | 1330.96M | 1118.37M |
| Intangible assets | 74.60M | 174.22M | 155.28M | 3.41M | 4.68M |
| Other current assets | 16.20M | 12.44M | 12.23M | 1099.09M | 1.44M |
| Total liab | 731.60M | 629.61M | 589.93M | 586.65M | 647.16M |
| Total stockholder equity | 1002.10M | 1040.55M | 1251.37M | 744.31M | 471.21M |
| Other current liab | 217.40M | 164.71M | 140.07M | 260.88M | 211.36M |
| Common stock | 0.10M | 0.04M | 0.04M | 0.03M | 0.03M |
| Capital stock | 0.10M | 0.04M | 0.04M | 0.03M | 0.03M |
| Retained earnings | -1958.50M | -1661.74M | -1484.71M | -966.46M | -816.97M |
| Other liab | - | - | - | 7.89M | 244.84M |
| Other assets | - | - | 0.00M | 67.68M | 7.32M |
| Cash | 901.90M | 286.75M | 1278.07M | 786.03M | 688.94M |
| Total current liabilities | 636.40M | 277.64M | 216.42M | 297.79M | 280.27M |
| Current deferred revenue | 11.30M | 47.41M | 53.01M | 0.45M | 60.95M |
| Net debt | -488.20M | 63.85M | -949.40M | -501.50M | -565.97M |
| Short term debt | 326.50M | 4.79M | 3.17M | 3.56M | 0.91M |
| Short long term debt | 319.10M | - | - | - | - |
| Short long term debt total | 413.70M | 350.60M | 328.67M | 284.53M | 122.97M |
| Other stockholder equity | 2838.30M | 2770.40M | 2637.12M | 744.31M | 816.97M |
| Property plant equipment | - | - | - | 160.76M | 152.91M |
| Total current assets | 1247.10M | 1283.92M | 1497.80M | 1099.12M | 948.75M |
| Long term investments | 5.00M | 4.36M | 4.36M | 0.00M | 4.71M |
| Net tangible assets | - | - | - | 740.90M | 466.52M |
| Short term investments | 46.70M | 835.93M | 31.00M | 239.62M | 193.46M |
| Net receivables | 250.30M | 124.89M | 157.06M | 0.09M | 63.16M |
| Long term debt | - | 301.20M | 281.33M | 260.93M | 120.46M |
| Inventory | 32.00M | 23.90M | 19.43M | 10.35M | 1.75M |
| Accounts payable | 81.20M | 37.19M | 20.16M | 32.89M | 7.04M |
| Accumulated other comprehensive income | 122.20M | -68.16M | 98.92M | 744.28M | 471.18M |
| Non currrent assets other | 5.00M | 6.06M | 152.42M | 66.76M | 5.15M |
| Non current assets total | 486.60M | 386.24M | 350.81M | 231.84M | 169.62M |
| Capital lease obligations | 94.60M | 49.41M | 47.34M | 23.60M | 2.50M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 777.00M | -850.54M | 92.79M | -78.34M | -194.98M |
| Change to liabilities | - | - | - | 32.03M | -20.43M |
| Total cashflows from investing activities | 711.48M | -850.54M | 92.79M | -77.09M | -194.98M |
| Net borrowings | -3.60M | -4.02M | -3.75M | -2.60M | -1.42M |
| Total cash from financing activities | -0.30M | 5.70M | 791.49M | 377.98M | 626.66M |
| Change to operating activities | - | - | - | 118.75M | 136.73M |
| Net income | -297.58M | -158.13M | -520.12M | -445.72M | -386.21M |
| Change in cash | 615.09M | -990.96M | 491.68M | 97.09M | 233.25M |
| Begin period cash flow | 286.82M | 1277.71M | 786.03M | 688.94M | 455.69M |
| End period cash flow | 901.90M | 286.75M | 1277.71M | 786.03M | 688.94M |
| Total cash from operating activities | -100.47M | -144.03M | -393.28M | -200.03M | -198.47M |
| Issuance of capital stock | 0.00M | 0.00M | 583.69M | 377.64M | 623.44M |
| Depreciation | 28.98M | 23.36M | 20.45M | 18.39M | 13.92M |
| Other cashflows from investing activities | - | -54.34M | -100.52M | -13.45M | -194.98M |
| Change to inventory | -4.51M | -17.21M | -12.71M | -8.61M | 0.05M |
| Change to account receivables | -132.85M | 93.75M | -98.98M | 50.32M | 24.59M |
| Other cashflows from financing activities | -3.61M | 9.72M | 795.25M | 2.93M | 4.64M |
| Change to netincome | - | - | - | 34.18M | 187.74M |
| Capital expenditures | 67.58M | 14.11M | 22.72M | 22.27M | 47.11M |
| Change in working capital | -93.35M | 20.04M | -71.34M | 186.32M | 140.87M |
| Stock based compensation | 64.60M | 68.94M | 47.68M | 34.34M | 20.16M |
| Other non cash items | 261.49M | -98.24M | 130.06M | 6.65M | 187.74M |
| Free cash flow | -168.04M | -158.14M | -416.00M | -222.30M | -245.58M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech Corp |
-0.23 1.02% |
22.30 | - | 27.62 | 2.70 | 2.93 | 2.29 | 253.69 |
| NVO Novo Nordisk A/S |
0.85 2.22% |
39.14 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
10.31 1.95% |
540.00 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
5.50 0.68% |
818.77 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
790.15 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
2101 Cottontail Lane, Somerset, NJ, United States, 08873
737 317 5050
3200
| Name | Title | Year Born |
|---|---|---|
| Dr. Ying Huang Ph.D. | CEO & Director | 1973 |
| Ms. Lori A. Macomber CPA | Chief Financial Officer | NA |
| Joanne Choi | Sr. Mang. of Investor Relations | NA |
| Mr. Marc Harrison | VP & Gen. Counsel | NA |
| Deborah Wong | Exec. Director of Strategic Marketing & Corp. Communications | NA |
| Ms. Liz Gosen | Sr. VP of Global Technical Operations | NA |
| Dr. Yuhong Qiu Ph.D. | Sr. VP of Global Regulatory Affairs | NA |
| Dr. Guowei Fang Ph.D. | Sr. VP & Global Head of Research and Early Devel. | NA |
| Mr. Steven J. Gavel | Sr. VP of Commercial Devel., US & Europe | NA |
| Mr. Alan Kick | Sr. VP of Global Quality | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.52%
Communication Services
+0.32%
Consumer Cyclical
+1.01%
Consumer Defensive
+0.00%
Energy
+0.01%
Financial Services
+0.62%
Financials
-2.62%
Healthcare
+0.51%
Industrials
+0.71%
Real Estate
+0.72%
Technology
-0.46%
Utilities
+0.54%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...